Land: Sydafrika
Språk: engelska
Källa: South African Health Products Regulatory Authority (SAHPRA)
Knoll
INDICATIONS [/za_1126.html#1] [/za_1126.html#1] [/za_1126.html#1] CONTRA-INDICATIONS [/za_1126.html#1] [/za_1126.html#1] DOSAGE [/za_1126.html#1] [/za_1126.html#1] SIDE-EFFECTS [/za_1126.html#1] [/za_1126.html#1] [/za_1126.html#1] PREGNANCY [/za_1126.html#1] [/za_1126.html#1] OVERDOSE [/za_1126.html#1] IDENTIFICATION [/za_1126.html#1] [/za_1126.html#1] PATIENT INFORMATION FROBEN SR : CAPSULES SCHEDULING STATUS S3 PROPRIETARY NAME (and dosage form) FROBEN SR : CAPSULES COMPOSITION Each hard gelatin capsule contains 200 mg of FLURBIPROFEN in a sustained release form. PHARMACOLOGICAL CLASSIFICATION A3.1/Antirheumatic (anti-inflammatory agent) PHARMACOLOGICAL ACTION FROBEN SR is a non-steroidal anti-inflammatory agent which has significant anti-inflammatory, analgesic and anti- pyretic properties. It is an inhibitor of prostaglandin synthetase enzymes which are known to be associated with inflammation, pain and fever. FROBEN SR is a sustained release formulation of flurbiprofen. During a 24 hour period at steady state, mean plasma levels are identical to those achieved with an equivalent daily dose of conventional FROBEN but with a marked reduction in the variation between maximum and minimum plasma concentrations. The elimination half life of flurbiprofen is unchanged (i.e. 3.5 hours), therefore, unlike drugs with intrinsically long half lives, no accumulation occurs with repeat dosing of FROBEN SR. INDICATIONS FROBEN SR is indicated for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. CONTRA-INDICATIONS The use of FROBEN SR is contra-indicated in patients with a history of peptic ulcer and gastro-intestinal bleeding. In patients with impaired hepatic or renal function FROBEN SR should be used with caution. FROBEN SR should Läs hela dokumentet